Pancreatic Cancer Research

ResearcherKyoto Prefectural University of MedicineActive in the last 2 years

Eigo Otsuji

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3260-8155; OpenAlex author ID A5041985650. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
14
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers

Papers 13

  1. Cancer-Derived Small Extracellular Vesicles Affect Vascular Endothelial Cells and Promote Adhesiveness of Pancreatic Cancer Cells. Last author DOI 10.1097/mpa.0000000000002346↗
  2. Urinary microRNA-210-3p as a novel and non-invasive biomarker for the detection of pancreatic cancer, including intraductal papillary mucinous carcinoma. Last author DOI 10.1186/s12885-024-12676-x↗
  3. Roles of voltage‑gated potassium channels in the maintenance of pancreatic cancer stem cells. Last author DOI 10.3892/ijo.2021.5256↗
  4. Photodynamic diagnosis of peritoneal metastasis in human pancreatic cancer using 5-aminolevulinic acid during staging laparoscopy. Last author DOI 10.3892/ol.2018.8732↗
  5. miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer. Co-author DOI 10.1038/s41598-017-04191-w↗
  6. Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer. Last author DOI 10.1038/s41598-017-06137-8↗
  7. Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids. Last author DOI 10.3748/wjg.v22.i25.5627↗
  8. Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer. Last author DOI 10.1038/bjc.2015.366↗
  9. Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in the prognosis. Last author DOI 10.1016/j.pan.2014.09.006↗
  10. The clinical impact of the lymph node ratio as a prognostic factor after resection of pancreatic cancer. Last author PMID 24778048↗
  11. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Last author DOI 10.1038/bjc.2012.546↗
  12. Enhancement of the cytocidal effects of hypotonic solution using a chloride channel blocker in pancreatic cancer cells. Last author DOI 10.1016/j.pan.2012.08.003↗
  13. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Last author DOI 10.1038/bjc.2011.453↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atsushi Shiozaki · 11 shared papers, 2011–2024 · strength 0.78
  2. Ryo Morimura · 10 shared papers, 2011–2024 · strength 0.64
  3. Daisuke Ichikawa · 9 shared papers, 2011–2017 · strength 0.37
  4. Taisuke Imamura · 4 shared papers, 2015–2024 · strength 0.34
  5. Yusuke Yamamoto · 3 shared papers, 2014–2024 · strength 0.26
  6. Hirotaka Furuke · 1 shared paper, 2024 · strength 0.18
  7. Jun Shibamoto · 1 shared paper, 2024 · strength 0.18
  8. Mahito Miyamae · 3 shared papers, 2015–2017 · strength 0.15
  9. Tsutomu Kawaguchi · 3 shared papers, 2013–2016 · strength 0.12
  10. Hidemasa Kubo · 1 shared paper, 2018 · strength 0.08
  11. Kyoichi Harada · 1 shared paper, 2018 · strength 0.08
  12. Hidekazu Hiramoto · 1 shared paper, 2017 · strength 0.08
  13. Johji Inazawa · 1 shared paper, 2017 · strength 0.08
  14. Yoshito Nako · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.